U.S. markets close in 3 hours 14 minutes

  • S&P 500

    3,865.81
    -34.30 (-0.88%)
     

  • Dow 30

    31,281.51
    -156.75 (-0.50%)
     

  • Nasdaq

    11,331.02
    -193.53 (-1.68%)
     

  • Russell 2000

    1,759.32
    -12.42 (-0.70%)
     

  • Crude Oil

    112.04
    +2.47 (+2.25%)
     

  • Gold

    1,823.70
    -1.10 (-0.06%)
     

  • Silver

    20.86
    -0.31 (-1.46%)
     

  • EUR/USD

    1.0536
    -0.0050 (-0.47%)
     

  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     

  • GBP/USD

    1.2208
    -0.0062 (-0.51%)
     

  • USD/JPY

    136.1440
    +0.6980 (+0.52%)
     

  • BTC-USD

    20,733.72
    -9.96 (-0.05%)
     

  • CMC Crypto 200

    451.09
    +1.03 (+0.23%)
     

  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     

  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • MRNS

  • Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD).

  • An application filing notification letter from the FDA is expected before the end of Q3 2021.

  • If the application is accepted for filing by the FDA, the Company will be able to draw $30 million of additional cash under its credit financing agreement with Oaktree Capital Management.

  • The application is supported by Phase 3 trial data in which 101 patients treated with ganaxolone showed a 30.7% median reduction in 28-day major motor seizure frequency, compared to a 6.9% reduction on placebo.

  • The Company also said that due to COVID-19 related priorities, data readout from Ganaxolone Phase 3 RAISE trial is expected in 2H of 2022. The majority of the clinical sites are expected to open by the end of Q3 2021.

  • Separately, Orion Corporation received exclusive rights to commercialize ganaxolone oral and intravenous dose formulations in Europe for CDKL5 deficiency disorder, tuberous sclerosis complex, and refractory status epilepticus.

  • Orion will pay Marinus €25 million as an upfront fee to Marinus and an additional €97 million in R&D reimbursement and cash milestone payments.

  • Price Action: MRNS shares are up 1.1% at $15.2 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories

  • ‘Simply Outrageous:’ EY Hit With $100 Million Fine After Audit Employees Cheat on CPA Ethics Exam

    (Bloomberg) -- Ernst & Young LLP admitted that dozens of its audit personnel cheated on the ethics portion of the Certified Public Accountant exam and that the firm misled US regulators probing the misconduct, according to the Securities and Exchange Commission.Most Read from BloombergRussia Slips Into Historic Default as Sanctions Muddy Next StepsMichael Burry of ‘The Big Short’ Fame Warns Fed May Alter CourseAnti-Abortion Centers Find Pregnant Teens Online, Then Save Their DataChina Cuts Trave

  • Why Carvana Stock Is Falling Hard Today

    Shares of the online car-buying company Carvana (NYSE: CVNA) were plunging this morning, likely after a Barron's article published over the weekend said that the company, in some cases, sold cars before it even had the title to them. Barron's said in its reporting that Carvana was selling cars too quickly during the pandemic, when demand for buying a car online soared, which led to problems in receiving the proper title for vehicles for some customers. Apparently, enough people have experienced this problem that a lawsuit is being brought against the car seller, saying that some customers went years without legally being able to drive vehicles purchased from Carvana.

  • Cathie Wood Says She Got Inflation Wrong, Continues Ark Strategy

    (Bloomberg) -- Cathie Wood on Tuesday said she erred in her prediction inflation would unravel as the prices of goods and services in the US soared to 40-year highs. Most Read from BloombergRussia Slips Into Historic Default as Sanctions Muddy Next StepsMichael Burry of ‘The Big Short’ Fame Warns Fed May Alter CourseAnti-Abortion Centers Find Pregnant Teens Online, Then Save Their DataChina Cuts Travel Quarantine in Biggest Covid Zero Shift YetA $2 Trillion Free-Fall Rattles Crypto to the Core“W

  • ‘They’ll chicken out’: Fund legend Rick Rule says the Fed won’t keep hiking rates aggressively to prevent ‘amazing damage.’ Here are 3 spots he likes for your dough

    Don’t count on the Fed. Get ready instead.

  • 2 “Strong Buy” Dividend Stocks With at Least 7% Dividend Yield

    We’re facing a maelstrom of conflicting currents in the markets today, with a series of headwinds running head-on into each other. Consumer sentiment is low – in fact, at the lowest levels ever recorded, with 79% of consumers expecting economic conditions to get worse in the coming year. Inflation is high, at levels not seen since 1981, and is expected to remain elevated through the end of 2023. Fuel prices are major driver with the national average for a gallon of gasoline exceeding $5. The hou

  • 3 Reasons Tesla Could Soar After Its Stock Split

    Despite tough odds, plenty of doubters, and regular criticism over its actions, Tesla (NASDAQ: TSLA) has developed into the leading manufacturer of electric vehicles globally. The automaker has grown rapidly, and so has its share price. Like all stock splits, the increase in the number of shares and the resulting share price drop doesn't actually change the intrinsic value of each share or of the company overall.

  • 10 Best Dividend Stocks For Inflation

    In this article, we discuss the 10 best dividend stocks for inflation. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best Dividend Stocks For Inflation. The current market situation is intense, and could potentially worsen with further rate hikes as warned by the Fed. […]

  • Oil Tanker Is Stopped by U.S. in Transit From Russian Port to New Orleans

    The ship carrying oil products was chartered by a Swiss-based commodities trader that said it complied with sanctions against Russia.

  • Elon Musk demanded Tesla staff return to the office – but it has gone wrong already, report says

    Mr Musk banned remote work and said employees must be in the office for a minimum of 40 hours per week

  • Warren Buffett’s Berkshire Hathaway buys more Occidental Petroleum stock

    Yahoo Finance Live anchors discuss Berkshire Hathaway buying more Occidental Petroleum stock.

  • Russian Industry Faces Code Crisis as IT Providers Pull Out

    (Bloomberg) -- Russia’s reliance on foreign software to run its factories, farms and oil fields is turning into one of the biggest headaches for domestic industry as more IT providers pull out of the market in response to President Vladimir Putin’s invasion of Ukraine. Most Read from BloombergRussia Slips Into Historic Default as Sanctions Muddy Next StepsMichael Burry of ‘The Big Short’ Fame Warns Fed May Alter CourseAnti-Abortion Centers Find Pregnant Teens Online, Then Save Their DataChina Cu

  • 3 Reasons to Buy Novavax and 1 to Sell

    Novavax (NASDAQ: NVAX) is a pandemic stock. Now it's down to $50, and the company's market cap is under $4 billion. Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.

  • China Loosens Its Covid Quarantine Rules. These Travel Stocks Are Flying.

    Travelers to China will now be isolated for seven days in a centralized location before monitoring their health for a further three days at home.

  • Hedge Funds Brace for Impact: Top 10 Stocks to Dump Now

    In this article, we discuss the top 10 stocks to dump now according to hedge funds as they brace for impact. If you want to see more stocks in this list, click Hedge Funds Brace for Impact: Top 5 Stocks to Dump Now. Elite hedge funds in the United States are exceedingly cautious with their […]

  • 3 Stock-Split Stocks You Can Confidently Buy and Hold Forever

    Among the high-profile stocks splitting their shares in 2022, these three offer the most attractive long-term growth prospects.

  • Jupiter CEO Quits $68 Billion Firm to Sit at the Beach and ‘Do Nothing’

    (Bloomberg) -- Andrew Formica, the chief executive officer of Jupiter Fund Management Plc, suddenly announced he’s leaving the £55.3 billion ($67.9 billion) asset manager he joined in 2019.Most Read from BloombergRussia Slips Into Historic Default as Sanctions Muddy Next StepsMichael Burry of ‘The Big Short’ Fame Warns Fed May Alter CourseAnti-Abortion Centers Find Pregnant Teens Online, Then Save Their DataChina Cuts Travel Quarantine in Biggest Covid Zero Shift YetA $2 Trillion Free-Fall Rattl

  • 'There is no more retirement': Retirees are heading back to work amid soaring inflation — here's what you need to know

    Not everyone can afford to live on fixed incomes as prices rise.

  • New to Dividend Stocks? Start by Buying These 3 Ultra-Safe Picks

    Investors might be skeptical to put their money in the stock market now given the current market scenario. Excellent growth stocks are trading at a bargain now. Investors new to dividend stocks can consider these three that belong to an exclusive group of Dividend Kings.

  • Early lupus patient data sends Kezar Life Sciences' stock soaring after-hours

    The company's stock also took a substantial dive early last month after the same drug missed its mark in two other diseases.

  • JetBlue sweetens offer for Spirit Airlines ahead of vote on Frontier bid

    Yahoo Finance Live’s Brian Sozzi breaks down JetBlue’s proposal for acquisition of Spirit Airlines.